Hysbysiad contract
Adran I:
Endid
contractio
I.1) Enw a chyfeiriad
NHS England
Wellington House, 133-135 Waterloo Rd
London
SE1 8UG
UK
Person cyswllt: Jessica Gaucher-Thompson
E-bost: jessica.gaucher-thompson@nhs.net
NUTS: UKJ1
Cyfeiriad(au) rhyngrwyd
Prif gyfeiriad: https://www.england.nhs.uk/
Cyfeiriad proffil y prynwr: https://www.england.nhs.uk/
I.3) Cyfathrebu
Mae'r dogfennau caffael ar gael ar gyfer mynediad uniongyrchol anghyfyngedig a llawn, yn rhad ac am ddim ar:
https://health-family.force.com/s/Welcome
Gellir cael gwybodaeth ychwanegol o'r cyfeiriad uchod
Rhaid anfon tendrau neu geisiadau i gymryd rhan yn electronig at:
https://health-family.force.com/s/Welcome
Rhaid anfon tendrau neu geisiadau i gymryd rhan i'r cyfeiriad uchod:
Mae cyfathrebu electronig yn gofyn am ddefnyddio offer a dyfeisiau nad ydynt ar gael yn gyffredinol. Mae mynediad uniongyrchol anghyfgyfyngiedig a llawn i'r offer a dyfeisiau hyn yn bosibl, yn rhad ac am ddim, yn:
https://health-family.force.com/s/Welcome
I.4) Y math o awdurdod contractio
Corff a lywodraethir gan gyfraith gyhoeddus
I.5) Prif weithgaredd
Iechyd
Adran II: Gwrthrych
II.1) Cwmpas y caffaeliad
II.1.1) Teitl
Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults)
II.1.2) Prif god CPV
85100000
II.1.3) Y math o gontract
Gwasanaethau
II.1.4) Disgrifiad byr
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England -Specialised Commissioning (referred to as the Authority), is inviting suitably qualified and experienced providers to respond to this Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).<br/><br/>As a result of this procurement exercise an agreement will be established with the successful bidder(s) for a period of three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration 5 years).<br/><br/>The deadline for submissions is 12.00pm (noon) on Tuesday 24th June 2025.
II.1.5) Cyfanswm gwerth amcangyfrifedig
Gwerth heb gynnwys TAW: 69 970 000.00 GBP
II.1.6) Gwybodaeth am lotiau
Mae’r contract hwn wedi’i rannu’n lotiau:
Ydy
Gellir cyflwyno tendrau ar gyfer un lot yn unig
Uchafswm y lotiau y gellir eu dyfarnu i un tendrwr: 1
II.2) Disgrifiad
Rhif y Lot 1
II.2.1) Teitl
Lot 1 - London (2 Sites)
II.2.2) Cod(au) CPV ychwanegol
85100000
II.2.3) Man cyflawni
Cod NUTS:
UKI
II.2.4) Disgrifiad o’r caffaeliad
The key objectives of the Procurement are to commission eight (8) Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adult patients, for the provision of Lifileucel for previously treated unresectable or metastatic melanoma, with two (2) sites in London. <br/><br/>Providers may only bid for one Lot. Bids submitted for multiple lots will not be considered. <br/><br/>Bidders are to note that Providers must be located in and deliver services from the defined geographical area(s) that they are interested in providing services to. <br/><br/>Link to NHS England Regions:<br/>NHS England » Regional teams (https://www.england.nhs.uk/about/regional-area-teams/).<br/><br/>As a result of this procurement exercise an agreement will be established with the successful bidder(s) for a period of three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration 5 years).<br/><br/>The deadline for submissions is 12.00pm (noon) on Tuesday 24th June 2025.
II.2.5) Meini prawf dyfarnu
Nid pris yw’r unig faen prawf dyfarnu a dim ond yn y dogfennau caffael y mae’r holl feini prawf wedi’u nodi
II.2.6) Gwerth amcangyfrifedig
Gwerth heb gynnwys TAW: 17 470 000.00 GBP
II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig
Dechrau:
31/10/2025
Diwedd:
30/10/2030
Gall y contract hwn gael ei adnewyddu: Na
II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd
II.2.10) Gwybodaeth am amrywiadau
Derbynnir amrywiadau:
Na
II.2.11) Gwybodaeth am opsiynau
Opsiynau:
Ydy
Disgrifiad o’r opsiynau:
Following the initial 3 year contract period, there is an option to extend for up to an additional 2 year(s)
II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd
Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd:
Na
Rhif y Lot 2
II.2.1) Teitl
Lot 2 - East of England (1 Site)
II.2.2) Cod(au) CPV ychwanegol
85100000
II.2.3) Man cyflawni
Cod NUTS:
UKH
II.2.4) Disgrifiad o’r caffaeliad
The key objectives of the Procurement are to commission eight (8) Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adult patients, for the provision of Lifileucel for previously treated unresectable or metastatic melanoma, with one (1) site in the East of England. <br/><br/>Providers may only bid for one Lot. Bids submitted for multiple lots will not be considered. <br/><br/>Bidders are to note that Providers must be located in and deliver services from the defined geographical area(s) that they are interested in providing services to. <br/><br/>Link to NHS England Regions:<br/>NHS England » Regional teams (https://www.england.nhs.uk/about/regional-area-teams/).<br/><br/>As a result of this procurement exercise an agreement will be established with the successful bidder(s) for a period of three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration 5 years).<br/><br/>The deadline for submissions is 12.00pm (noon) on Tuesday 24th June 2025.
II.2.5) Meini prawf dyfarnu
Nid pris yw’r unig faen prawf dyfarnu a dim ond yn y dogfennau caffael y mae’r holl feini prawf wedi’u nodi
II.2.6) Gwerth amcangyfrifedig
Gwerth heb gynnwys TAW: 8 740 000.00 GBP
II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig
Dechrau:
31/10/2025
Diwedd:
30/10/2030
Gall y contract hwn gael ei adnewyddu: Na
II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd
II.2.10) Gwybodaeth am amrywiadau
Derbynnir amrywiadau:
Na
II.2.11) Gwybodaeth am opsiynau
Opsiynau:
Ydy
Disgrifiad o’r opsiynau:
Following the initial 3 year contract period, there is an option to extend for up to an additional 2 year(s)
II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd
Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd:
Na
Rhif y Lot 3
II.2.1) Teitl
Lot 3 - South East (1 Site)
II.2.2) Cod(au) CPV ychwanegol
85100000
II.2.3) Man cyflawni
Cod NUTS:
UKJ
II.2.4) Disgrifiad o’r caffaeliad
The key objectives of the Procurement are to commission eight (8) Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adult patients, for the provision of Lifileucel for previously treated unresectable or metastatic melanoma, with one (1) site in the South East. <br/><br/>Providers may only bid for one Lot. Bids submitted for multiple lots will not be considered. <br/><br/>Bidders are to note that Providers must be located in and deliver services from the defined geographical area(s) that they are interested in providing services to. <br/><br/>Link to NHS England Regions:<br/>NHS England » Regional teams (https://www.england.nhs.uk/about/regional-area-teams/).<br/><br/>As a result of this procurement exercise an agreement will be established with the successful bidder(s) for a period of three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration 5 years).<br/><br/>The deadline for submissions is 12.00pm (noon) on Tuesday 24th June 2025.
II.2.5) Meini prawf dyfarnu
Nid pris yw’r unig faen prawf dyfarnu a dim ond yn y dogfennau caffael y mae’r holl feini prawf wedi’u nodi
II.2.6) Gwerth amcangyfrifedig
Gwerth heb gynnwys TAW: 8 740 000.00 GBP
II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig
Dechrau:
31/10/2025
Diwedd:
30/10/2030
Gall y contract hwn gael ei adnewyddu: Na
II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd
II.2.10) Gwybodaeth am amrywiadau
Derbynnir amrywiadau:
Na
II.2.11) Gwybodaeth am opsiynau
Opsiynau:
Ydy
Disgrifiad o’r opsiynau:
Following the initial 3 year contract period, there is an option to extend for up to an additional 2 year(s)
II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd
Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd:
Na
Rhif y Lot 4
II.2.1) Teitl
Lot 4 - South West (1 Site)
II.2.2) Cod(au) CPV ychwanegol
85100000
II.2.3) Man cyflawni
Cod NUTS:
UKK
II.2.4) Disgrifiad o’r caffaeliad
The key objectives of the Procurement are to commission eight (8) Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adult patients, for the provision of Lifileucel for previously treated unresectable or metastatic melanoma, with one (1) site in the South West. <br/><br/>Providers may only bid for one Lot. Bids submitted for multiple lots will not be considered. <br/><br/>Bidders are to note that Providers must be located in and deliver services from the defined geographical area(s) that they are interested in providing services to. <br/><br/>Link to NHS England Regions:<br/>NHS England » Regional teams (https://www.england.nhs.uk/about/regional-area-teams/).<br/><br/>As a result of this procurement exercise an agreement will be established with the successful bidder(s) for a period of three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration 5 years).<br/><br/>The deadline for submissions is 12.00pm (noon) on Tuesday 24th June 2025.
II.2.5) Meini prawf dyfarnu
Nid pris yw’r unig faen prawf dyfarnu a dim ond yn y dogfennau caffael y mae’r holl feini prawf wedi’u nodi
II.2.6) Gwerth amcangyfrifedig
Gwerth heb gynnwys TAW: 8 740 000.00 GBP
II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig
Dechrau:
31/10/2025
Diwedd:
30/10/2030
Gall y contract hwn gael ei adnewyddu: Na
II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd
II.2.10) Gwybodaeth am amrywiadau
Derbynnir amrywiadau:
Na
II.2.11) Gwybodaeth am opsiynau
Opsiynau:
Ydy
Disgrifiad o’r opsiynau:
Following the initial 3 year contract period, there is an option to extend for up to an additional 2 year(s)
II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd
Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd:
Na
Rhif y Lot 5
II.2.1) Teitl
Lot 5 - Midlands (1 Site)
II.2.2) Cod(au) CPV ychwanegol
85100000
II.2.3) Man cyflawni
Cod NUTS:
UKF
UKG
II.2.4) Disgrifiad o’r caffaeliad
The key objectives of the Procurement are to commission eight (8) Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adult patients, for the provision of Lifileucel for previously treated unresectable or metastatic melanoma, with one (1) site in the Midlands. <br/><br/>Providers may only bid for one Lot. Bids submitted for multiple lots will not be considered. <br/><br/>Bidders are to note that Providers must be located in and deliver services from the defined geographical area(s) that they are interested in providing services to. <br/><br/>Link to NHS England Regions:<br/>NHS England » Regional teams (https://www.england.nhs.uk/about/regional-area-teams/).<br/><br/>As a result of this procurement exercise an agreement will be established with the successful bidder(s) for a period of three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration 5 years).<br/><br/>The deadline for submissions is 12.00pm (noon) on Tuesday 24th June 2025.
II.2.5) Meini prawf dyfarnu
Nid pris yw’r unig faen prawf dyfarnu a dim ond yn y dogfennau caffael y mae’r holl feini prawf wedi’u nodi
II.2.6) Gwerth amcangyfrifedig
Gwerth heb gynnwys TAW: 8 740 000.00 GBP
II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig
Dechrau:
31/10/2025
Diwedd:
30/10/2030
Gall y contract hwn gael ei adnewyddu: Na
II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd
II.2.10) Gwybodaeth am amrywiadau
Derbynnir amrywiadau:
Na
II.2.11) Gwybodaeth am opsiynau
Opsiynau:
Ydy
Disgrifiad o’r opsiynau:
Following the initial 3 year contract period, there is an option to extend for up to an additional 2 year(s)
II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd
Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd:
Na
Rhif y Lot 6
II.2.1) Teitl
Lot 6 - North East and Yorkshire (1 Site)
II.2.2) Cod(au) CPV ychwanegol
85100000
II.2.3) Man cyflawni
Cod NUTS:
UKC
UKE
II.2.4) Disgrifiad o’r caffaeliad
The key objectives of the Procurement are to commission eight (8) Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adult patients, for the provision of Lifileucel for previously treated unresectable or metastatic melanoma, with one (1) site in the North East and Yorkshire.<br/><br/>Providers may only bid for one Lot. Bids submitted for multiple lots will not be considered. <br/><br/>Bidders are to note that Providers must be located in and deliver services from the defined geographical area(s) that they are interested in providing services to. <br/><br/>Link to NHS England Regions:<br/>NHS England » Regional teams (https://www.england.nhs.uk/about/regional-area-teams/).<br/><br/>As a result of this procurement exercise an agreement will be established with the successful bidder(s) for a period of three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration 5 years).<br/><br/>The deadline for submissions is 12.00pm (noon) on Tuesday 24th June 2025.
II.2.5) Meini prawf dyfarnu
Nid pris yw’r unig faen prawf dyfarnu a dim ond yn y dogfennau caffael y mae’r holl feini prawf wedi’u nodi
II.2.6) Gwerth amcangyfrifedig
Gwerth heb gynnwys TAW: 8 740 000.00 GBP
II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig
Dechrau:
31/10/2025
Diwedd:
30/10/2030
Gall y contract hwn gael ei adnewyddu: Na
II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd
II.2.10) Gwybodaeth am amrywiadau
Derbynnir amrywiadau:
Na
II.2.11) Gwybodaeth am opsiynau
Opsiynau:
Ydy
Disgrifiad o’r opsiynau:
Following the initial 3 year contract period, there is an option to extend for up to an additional 2 year(s)
II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd
Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd:
Na
Rhif y Lot 7
II.2.1) Teitl
Lot 7 - North West (1 Site)
II.2.2) Cod(au) CPV ychwanegol
85100000
II.2.3) Man cyflawni
Cod NUTS:
UKD
II.2.4) Disgrifiad o’r caffaeliad
The key objectives of the Procurement are to commission eight (8) Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adult patients, for the provision of Lifileucel for previously treated unresectable or metastatic melanoma, with one (1) site in the North West. <br/><br/>Providers may only bid for one Lot. Bids submitted for multiple lots will not be considered. <br/><br/>Bidders are to note that Providers must be located in and deliver services from the defined geographical area(s) that they are interested in providing services to. <br/><br/>Link to NHS England Regions:<br/>NHS England » Regional teams (https://www.england.nhs.uk/about/regional-area-teams/).<br/><br/>As a result of this procurement exercise an agreement will be established with the successful bidder(s) for a period of three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration 5 years).<br/><br/>The deadline for submissions is 12.00pm (noon) on Tuesday 24th June 2025.
II.2.5) Meini prawf dyfarnu
Nid pris yw’r unig faen prawf dyfarnu a dim ond yn y dogfennau caffael y mae’r holl feini prawf wedi’u nodi
II.2.6) Gwerth amcangyfrifedig
Gwerth heb gynnwys TAW: 8 740 000.00 GBP
II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig
Dechrau:
31/10/2025
Diwedd:
30/10/2030
Gall y contract hwn gael ei adnewyddu: Na
II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd
II.2.10) Gwybodaeth am amrywiadau
Derbynnir amrywiadau:
Na
II.2.11) Gwybodaeth am opsiynau
Opsiynau:
Ydy
Disgrifiad o’r opsiynau:
Following the initial 3 year contract period, there is an option to extend for up to an additional 2 year(s)
II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd
Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd:
Na
Section IV: Gweithdrefn
IV.1) Disgrifiad
IV.1.1) Y math o weithdrefn
Gweithdrefn agored
IV.1.8) Gwybodaeth am Gytundeb Caffael y Llywodraeth (GPA)
The procurement is covered by the Government Procurement Agreement:
Ydy
IV.2) Gwybodaeth weinyddol
IV.2.2) Terfyn amser i dendrau neu geisiadau i gymryd rhan ddod i law
Dyddiad:
24/06/2025
Amser lleol: 12:00
IV.2.4) Ym mha iaith/ieithoedd y gellir cyflwyno tendrau neu geisiadau i gymryd rhan
EN
IV.2.6) Yr isafswm cyfnod gofynnol i’r sawl sy’n tendro gynnal y tendr
Rhaid i’r tendr fod yn ddilys tan:
21/12/2025
IV.2.7) Amodau ar gyfer agor tendrau
Dyddiad:
24/06/2025
Amser lleol: 12:00
Section VI: Gwybodaeth ategol
VI.1) Gwybodaeth am ailddigwydd
Caffaeliad cylchol yw hwn:
Ydy
VI.3) Gwybodaeth ychwanegol
The key objectives of the Procurement are to commission eight (8) Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adult patients, for the provision of Lifileucel for previously treated unresectable or metastatic melanoma, across seven (7) geographical lots as outlined below, to serve the population of England. <br/><br/>Lot 1: London (2 sites)<br/>Lot 2: East of England (1 site)<br/>Lot 3: South East (1 site)<br/>Lot 4: South West (1 site)<br/>Lot 5: Midlands (1 site)<br/>Lot 6: North East and Yorkshire (1 site)<br/>Lot 7: North West (1 site)<br/><br/>Bidders are to note that Providers must be located in and deliver services from the defined geographical area(s) that they are interested in providing services to. <br/><br/>Link to NHS England Regions:<br/>NHS England » Regional teams (https://www.england.nhs.uk/about/regional-area-teams/). <br/><br/>Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a Trust with immediate access to Intensive Therapy Unit (ITU). <br/><br/>Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date of 10th December 2025. <br/><br/>Link for the current NICE paperwork:<br/>https://www.nice.org.uk/guidance/indevelopment/gid-ta10752<br/><br/>Providers are required to be an established site for the delivery of specialist skin cancer care that complies with the requirements as set out in the following specification: https://www.england.nhs.uk/wp-content/uploads/2018/08/Cancer-skin-adult.pdf<br/><br/>Providers must also;<br/>• Have access to surgical expertise which enables them to perform tumour resections to obtain enough sample tissue for final product to be made. <br/>• hold the appropriate Human Tissue Authority licences, which includes having the licence to cover the procurement, donor testing and exporting of the resected tissue.<br/>• Have expertise in delivering and managing cellular therapies <br/>• Have experience of managing the adverse effects of interleukin 2 inhibitors. Examples of these adverse events would be those similar to cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome.<br/>• Hold a Joint Accreditation Committee of ISCT and EBMT of the European Society for Blood and Marrow Transplantation (JACIE) Immune Effector Cells (IEC) accreditation or be working towards such accreditation. <br/>• Be a Heamotopoietic Stem Cell Transplantation centre <br/><br/>Providers must be able to meet the requirements set out in this Competitive Process and deliver the contract in accordance with its terms.<br/><br/>To express interest and participate in the Competitive Process, please register and apply via Atamis esourcing portal https://health-family.force.com/s/Welcome<br/><br/>Should Tenderers have any queries, or problems using the portal, they should contact the Helpdesk at: <br/>Phone: 0800 9956035<br/>E-mail: support-health@atamis.co.uk<br/><br/>The closing date for completed Competitive Process responses is 12:00pm (noon), on Tuesday 24th June 2025.<br/><br/>Atamis Project reference C41701<br/><br/>The contract duration is for three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration five (5) years).<br/><br/>This is a Provider Selection Regime (PSR) Contract Notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award.<br/><br/>The decision maker of the award will be: NHS England
VI.4) Gweithdrefnau adolygu
VI.4.1) Corff adolygu
NHS Arden and Greater East Midlands Commissioning Support Unit
Cardinal Square, 10 Nottingham Road
Derby
DE1 3QT
UK
Cyfeiriad(au) rhyngrwyd
URL: https://www.ardengemcsu.nhs.uk/
VI.5) Dyddiad anfon yr hysbysiad hwn
16/05/2025